FREE NABP NAPLEX Exam Guide + Pass Rate (2026)

NABP NAPLEX 2026: What Pharmacy Graduates Actually Need to Know

The North American Pharmacist Licensure Examination (NAPLEX) is the single national competency exam every PharmD graduate must pass to get licensed as a pharmacist in the United States. It is administered by the National Association of Boards of Pharmacy (NABP) and delivered at Pearson VUE test centers. Your state board of pharmacy uses your NAPLEX score (plus the MPJE and any state-specific requirements) to decide whether you can legally dispense and counsel on medications.

NAPLEX is not a memorization contest. It is a clinical-reasoning exam that asks: "Given this patient, this drug, and this data, what does a safe entry-level pharmacist do next?" That framing matters because candidates who pass on the first try are usually not the ones who read the most pages — they are the ones who practiced the most exam-style items and corrected their errors systematically.

This guide covers the current 2025-2026 NAPLEX Content Outline (effective May 1, 2025), the exact fees, format, 2025 first-time pass rate rebound, a 10-week study plan, the core pharmacokinetic and pharmaceutical calculations you cannot get wrong, high-yield disease-state priorities, and how the NAPLEX fits alongside the MPJE and BPS specialty certifications.

---

Start Your FREE NAPLEX Prep Today

Start FREE NAPLEX Practice QuestionsPractice questions with detailed explanations

Thousands of PharmD candidates are using our NAPLEX question bank with AI-powered explanations and pharmacokinetic calculation drills — 100% FREE.

---

NAPLEX 2026 Exam Format at a Glance

The "No Going Back" Rule

This is the single biggest format surprise for first-time takers: once you confirm an answer, it is locked. There is no review screen, no "flag for later," no end-of-section mop-up. Every question you see is your only attempt at that item. Practice this discipline in your final month by using full-length 225-question timed blocks with no backtracking.

NAPLEX Fees for 2026

Fees are set by NABP and are current as of the 2026 NAPLEX/MPJE Application Bulletin. Always confirm on your NABP e-Profile before paying.

Budget reality check: a PharmD grad seeking dual licensure in two states, with a score transfer and the Pre-NAPLEX, is realistically looking at $850-$950 in NABP fees alone — before any review course like UWorld RxPrep ($400-$700). Pass on the first try.

Eligibility: Who Can Take the NAPLEX

NAPLEX eligibility is a two-step approval:

1. NABP e-Profile application — you create an e-Profile, pay the $100 application fee, and link it to the board of pharmacy in the state where you want to be licensed.
2. Board of pharmacy approval — your state board verifies your PharmD transcript (from an ACPE-accredited college of pharmacy) and confirms you meet state-specific requirements.

Standard Eligibility Pathways

Retake rule: Most states require you to wait at least 45 days between attempts (some jurisdictions impose longer waits). You must also reapply through your NABP e-Profile, pay the $100 application fee again, and pay the $520 resit exam fee. A small number of state boards cap the total lifetime attempts (often 3-5 before requiring remediation).

---

Access FREE NAPLEX Practice Questions

Access FREE NAPLEX Practice QuestionsPractice questions with detailed explanations

Cover every domain of the current 2025-2026 NAPLEX Content Outline with detailed rationales, calculation drills, and clinical decision scenarios — 100% FREE.

---

NAPLEX 2026 Content Outline (Effective May 2025)

NABP fully overhauled the NAPLEX blueprint with the new NAPLEX Content Outline effective May 1, 2025, which continues to govern the 2026 exam. The old three-area "Competency Statement Areas" blueprint (67% / 18% / 15%) is retired. The current exam has five content domains, and the point distribution is very different.

Strategic implication: 65% of your score comes from Domains 2 and 3 combined. If you are running out of study time, you must be strong on Medication Use Process and Person-Centered Assessment and Treatment Planning. Domains 4 and 5 are each worth only 10 questions — know the basics, but do not over-invest review time there.

Domain 1 — Foundational Knowledge for Pharmacy Practice (25%)

This is the "basic science is clinical" domain. Expect questions on:

• Pharmacokinetics (PK): absorption, distribution, metabolism, excretion, half-life, volume of distribution, clearance
• Pharmacodynamics (PD): receptor binding, efficacy, potency, dose-response relationships
• Pharmacogenomics: CYP2C19 (clopidogrel), CYP2D6 (codeine, tamoxifen), TPMT (thiopurines), HLA-B57:01 (abacavir), HLA-B15:02 (carbamazepine)
• Drug chemistry, formulation, and stability
• Biostatistics and literature evaluation: p-values, confidence intervals, NNT/NNH, relative vs absolute risk reduction

Domain 2 — Medication Use Process (25%)

This is the operational safety domain — prescribing, dispensing, compounding, and administration.

• Prescription interpretation and verification (DEA numbers, Schedule II requirements, e-prescribing, refill rules)
• Sterile and non-sterile compounding (USP <795>, USP <797>, USP <800> hazardous drugs, beyond-use dating)
• IV admixtures, TPN, and parenteral compatibility
• Pharmaceutical calculations (mg/kg, mEq, mOsm, IV flow rates, drops/min, BSA, alligation, dilutions)
• Error prevention: look-alike/sound-alike (LASA), tall-man lettering, barcoding, automated dispensing cabinets
• Automation and technology: e-prescribing, CPOE, bar-code medication administration (BCMA)

Domain 3 — Person-Centered Assessment and Treatment Planning (40%)

This is the biggest domain by far — 80 scored questions. This is where disease-state clinical reasoning lives.

• Cardiovascular: HTN (ACC/AHA 2017, JNC guidelines), dyslipidemia (ACC/AHA, statin intensity), heart failure (GDMT: ARNI + BB + MRA + SGLT2), atrial fibrillation (CHA2DS2-VASc, DOACs), ACS, stroke
• Endocrine: type 2 diabetes (ADA Standards of Care, SGLT2/GLP-1 first-line for CV/renal benefit), thyroid, osteoporosis
• Infectious disease: empiric antibiotics, MRSA, VRE, C. difficile, HIV (PrEP, ART regimens), HCV, tuberculosis, antifungals, antivirals
• Oncology: chemotherapy classes, immunotherapy (checkpoint inhibitors), targeted therapy, supportive care (antiemetics, growth factors)
• Psychiatry: depression (SSRI/SNRI), anxiety, bipolar (lithium, valproate, lamotrigine), schizophrenia, ADHD, substance use disorders
• Pulmonology: asthma (GINA stepwise), COPD (GOLD)
• Special populations: pediatrics (weight-based dosing, fluids), geriatrics (Beers Criteria, renal dose adjust), pregnancy/lactation (LactMed)
• Drug-drug interactions: CYP450 inducers and inhibitors (see table below), QT-prolonging drug stacking, serotonin syndrome risk

Domain 4 — Professional Practice (5%)

• Patient counseling (OBRA-90 required elements)
• Health and wellness, immunization schedules (ACIP)
• Public health (opioid stewardship, naloxone, smoking cessation)
• Cultural competence and health literacy

Domain 5 — Pharmacy Management and Leadership (5%)

• Inventory, drug shortages, recalls (FDA Class I/II/III)
• Quality improvement (RCA, CQI, MUE, FMEA)
• Regulatory bodies (FDA, DEA, Joint Commission)
• Leadership, delegation, preceptor role

The NAPLEX Pass Rate: What the 2025 Data Actually Shows

The NAPLEX pass rate is the most-searched and most-misquoted NAPLEX statistic. Here are the real numbers directly from NABP's Ten-Year NAPLEX and MPJE Pass Rates report (prepared February 2026).

First-Time NAPLEX Pass Rates by Graduation Year (NABP, 2025 data release)

What This Means for 2026 Candidates

The 2022-2024 dip reflected a blueprint transition, pandemic-era clinical education disruption, and an expanded item pool. The 2025 first-time pass rate rebounded to 86.8% — essentially pre-pandemic levels. If you are a 2026 graduate, the current exam is behaving normally, not punitively. Candidates who fail today are overwhelmingly those who under-practiced timed question blocks, not those who hit an unfair exam.

The 10-12 Week Post-Graduation Study Plan

Most candidates take NAPLEX in the 6-8 weeks after PharmD graduation (May-July). The plan below assumes 30-40 study hours per week. Adjust ratios if you have a residency start date compressing your timeline.

Total Study Hour Benchmarks

• Full-time prep (8-10 weeks): 300-400 hours
• Residency-bound candidate (6-8 weeks): 240-320 hours
• Retake prep: 180-250 targeted hours with emphasis on the domain(s) you failed

Pharmacokinetics: The Math You Must Get Right

PK is the single most-tested calculation skill on NAPLEX. These are the equations you must perform in under 60 seconds each.

First-Order vs Zero-Order Elimination

• First-order (most drugs): a constant fraction of drug is eliminated per unit time. Half-life (t½) is constant regardless of concentration.
• Zero-order (ethanol, phenytoin at high doses, aspirin at toxic doses): a constant amount of drug is eliminated per unit time. Half-life is not constant — it depends on concentration.

Half-Life, Volume of Distribution, Clearance

The three core equations:

t½ = 0.693 × Vd / Cl
Cl = ke × Vd
ke = 0.693 / t½

• Steady state is reached in approximately 4-5 half-lives (regardless of dose or interval).
• Loading dose = Cp (target) × Vd / F
• Maintenance dose = Cp (target) × Cl × τ / F

Creatinine Clearance — Cockcroft-Gault

The Cockcroft-Gault equation is the reference standard for drug dose adjustment in renal impairment (not eGFR/MDRD for dosing).

CrCl (mL/min) = [(140 − age) × weight in kg] / [72 × SCr in mg/dL]
                (multiply by 0.85 if female)

Weight selection rules:

• If actual body weight (ABW) < ideal body weight (IBW): use ABW
• If ABW is between IBW and 1.3 × IBW: use IBW
• If ABW ≥ 1.3 × IBW (obese): use adjusted body weight = IBW + 0.4 × (ABW − IBW)

Ideal body weight (Devine):

• Male: 50 kg + 2.3 kg × (inches over 60)
• Female: 45.5 kg + 2.3 kg × (inches over 60)

Other Required Calculations

• mg/kg dosing (pediatric especially): always round appropriately to a commercially available strength
• mEq = (mass in mg × valence) / atomic weight
• mOsm = (grams of solute × number of species × 1000) / molecular weight
• IV flow rate (mL/hr) = total volume / hours; drops/min = (mL/hr × drop factor) / 60
• BSA (Mosteller) = √[(height in cm × weight in kg) / 3600]
• Alligation for percent-strength mixing
• Parenteral nutrition: dextrose kcal (3.4 kcal/g), protein (4 kcal/g), lipid (9 kcal/g or 10 kcal/g for 20% emulsion counting glycerol)

CYP450 Inducers and Inhibitors: The High-Yield DDI Table

Drug-drug interactions are embedded across Domains 1, 2, and 3. Memorize this table.

Major CYP3A4 Inhibitors (raise drug levels)

• Azole antifungals (ketoconazole, itraconazole, voriconazole, posaconazole)
• Macrolides (clarithromycin, erythromycin — not azithromycin)
• Protease inhibitors (ritonavir, cobicistat)
• Grapefruit juice
• Diltiazem, verapamil
• Nefazodone

Major CYP3A4 Inducers (lower drug levels)

• Rifampin, rifabutin
• Carbamazepine, phenytoin, phenobarbital
• St. John's Wort
• Efavirenz, nevirapine

Other Critical CYPs

Memory aid for major 3A4 inhibitors: "G PACMAN" — Grapefruit, Protease inhibitors, Azoles, Cimetidine/Cyclosporine, Macrolides, Amiodarone, Non-DHP CCBs.

High-Yield Disease-State Priorities (Domain 3)

These are the disease states that historically carry the highest question density. If you only have time to deeply master 10 topics, these are the 10:

1. Diabetes mellitus type 2 — ADA Standards of Care, metformin first-line, SGLT2 if CVD/HF/CKD, GLP-1 if ASCVD, insulin titration
2. Hypertension — ACC/AHA 2017 thresholds (≥130/80 stage 1), first-line agents by compelling indication
3. Heart failure (HFrEF) — GDMT quadruple therapy: ARNI (or ACEI/ARB) + beta-blocker + MRA + SGLT2 inhibitor
4. Atrial fibrillation — CHA2DS2-VASc scoring, DOAC selection, rate vs rhythm control
5. Dyslipidemia — statin intensity by ASCVD risk group, PCSK9/ezetimibe/bempedoic add-ons
6. Anticoagulation — warfarin reversal, DOAC dose by CrCl, bridging logic, HIT
7. Infectious disease — empiric antibiotics by infection site; community-acquired pneumonia; UTI; cellulitis/MRSA; sepsis
8. Asthma/COPD — GINA/GOLD stepwise; inhaler technique; ICS-LABA pairs
9. Pain management — opioid equianalgesic conversions, naloxone co-prescribing, NSAID risk
10. Psychiatric — SSRIs, serotonin syndrome, bipolar mood stabilizers, lithium toxicity, clozapine monitoring

Deep Dive: Diabetes Mellitus Type 2 (ADA 2026 Standards of Care)

Diabetes is one of the most predictable question generators on the NAPLEX. The ADA algorithm rewards candidates who understand why first-line agents are chosen, not just what they are.

First-Line Selection Framework

Key Drug Class Pearls

• Metformin — contraindicated if eGFR < 30; do not initiate if eGFR < 45; hold 48 hours around iodinated contrast if eGFR < 60. Risk of B12 deficiency with long-term use.
• SGLT2 inhibitors — risk of euglycemic DKA (especially perioperative), genital mycotic infections, Fournier gangrene (rare), volume depletion. Empagliflozin and dapagliflozin have HF and CKD indications independent of diabetes.
• GLP-1 RAs — GI side effects (nausea dose-dependent, titrate slowly), risk of pancreatitis, boxed warning for medullary thyroid carcinoma (MTC) and MEN2. Semaglutide oral requires fasting administration with ≤4 oz water, 30 min before food.
• DPP-4 inhibitors — weight-neutral, low hypoglycemia risk; saxagliptin and alogliptin carry HF warnings; do not combine with GLP-1 RA (redundant mechanism).
• Sulfonylureas (glipizide preferred; avoid glyburide in elderly per Beers) — risk of hypoglycemia and weight gain.
• Thiazolidinediones (pioglitazone) — avoid in HF; risk of weight gain, edema, fractures, bladder cancer.
• Insulin — basal (glargine, detemir, degludec), prandial (aspart, lispro, glulisine), premixed. Know onset/peak/duration cold.

Deep Dive: Hypertension (ACC/AHA 2017, Reaffirmed 2026)

BP Thresholds

First-Line Agents (Non-Black, No Compelling Indication)

Any of: thiazide diuretic (chlorthalidone preferred over HCTZ), ACEI, ARB, CCB (dihydropyridine).

Compelling Indication Overrides

Hyperkalemia alert combos to screen for: ACEI + ARB + MRA + K-sparing diuretic + trimethoprim-sulfamethoxazole. Never layer more than two.

Deep Dive: Anticoagulation Mastery

Anticoagulation questions span Domains 1, 2, and 3 and commonly include calculations. Know these cold.

Warfarin

• Narrow therapeutic index; target INR 2-3 for most indications; 2.5-3.5 for mechanical mitral valves
• Vitamin K antagonist — inhibits factors II, VII, IX, X and proteins C and S
• Initial procoagulant effect (protein C has shortest half-life) — bridge with heparin/LMWH for 5 days AND until INR ≥ 2 for 24 hours
• Reversal: Vitamin K (oral preferred if non-urgent), 4-factor PCC (Kcentra) for major bleeding, FFP if PCC unavailable
• Major interactions: amiodarone (↑INR), TMP-SMX (↑INR), fluconazole (↑INR), rifampin (↓INR), carbamazepine (↓INR), St. John's Wort (↓INR)

DOACs — Renal Dose Adjustments

DOAC Reversal

• Dabigatran → idarucizumab (Praxbind)
• Apixaban/rivaroxaban → andexanet alfa (Andexxa) or 4-factor PCC if andexanet unavailable
• Edoxaban → 4-factor PCC

Heparin-Induced Thrombocytopenia (HIT)

Platelet drop >50% or <100,000 between days 5-14 of heparin exposure. Stop ALL heparin (including flushes). Do NOT give platelets. Start non-heparin anticoagulant: argatroban (hepatic clearance, preferred in renal impairment) or bivalirudin. Transition to DOAC or warfarin only after platelet recovery (>150,000).

Deep Dive: Empiric Antibiotic Therapy by Infection Site

This table alone can earn you 10+ points on NAPLEX Domain 3.

Vancomycin Dosing and Monitoring

Target AUC24 400-600 mg·h/L (not trough-only) for serious MRSA infections per 2020 ASHP/IDSA consensus guidelines. Troughs of 15-20 mg/L are still acceptable where AUC monitoring is unavailable. Key toxicities: nephrotoxicity (especially with piperacillin-tazobactam), "red man syndrome" (histamine release — slow infusion), ototoxicity.

Deep Dive: Oncology Supportive Care

Oncology questions often target supportive care more than chemotherapy itself.

Chemotherapy-Induced Nausea and Vomiting (CINV) — NCCN Prevention

Febrile Neutropenia (ANC <500)

Medical emergency. Empiric broad-spectrum anti-pseudomonal beta-lactam (cefepime, meropenem, or piperacillin-tazobactam) within 1 hour. Add vancomycin if hemodynamic instability, MRSA risk, catheter infection, or skin/soft tissue source.

Tumor Lysis Syndrome (TLS)

Labs: ↑K, ↑phosphate, ↑uric acid, ↓calcium. Prophylaxis: IV fluids + allopurinol (low/moderate risk) or rasburicase (high risk — burkitt, AML with hyperleukocytosis). Do not give rasburicase in G6PD deficiency.

Oral Chemotherapy Pearls

• Capecitabine — dose-adjust for CrCl, hand-foot syndrome, DPD deficiency screening
• Imatinib — CYP3A4 substrate, watch for fluid retention
• Tamoxifen — CYP2D6 activation; avoid strong CYP2D6 inhibitors (paroxetine, fluoxetine)
• Methotrexate — monitor for nephrotoxicity, pneumonitis, mucositis; leucovorin rescue for high-dose; avoid NSAIDs and TMP-SMX (displaces from albumin, reduces clearance)

Deep Dive: Psychiatric Pharmacotherapy Pearls

Serotonin Syndrome

Triad: mental status changes + autonomic hyperactivity + neuromuscular abnormalities (clonus, hyperreflexia, tremor). High-risk combinations to recognize on NAPLEX:

• MAOI + SSRI/SNRI (requires 2-week washout; 5 weeks for fluoxetine)
• Linezolid + SSRI/SNRI (linezolid is a weak MAOI)
• Tramadol + SSRI
• Triptans + SSRI/SNRI (contested risk; usually not severe)
• Dextromethorphan + MAOI
• St. John's Wort + SSRI

Lithium Monitoring

• Therapeutic trough: 0.6-1.2 mEq/L (lower in maintenance, up to 1.5 in acute mania)
• Toxicity: tremor, confusion, ataxia, seizures at >1.5 mEq/L
• Interactions that raise lithium levels: NSAIDs, ACEI/ARBs, thiazides (decrease renal clearance)
• Monitor: Li level, renal function, thyroid function, ECG
• Pregnancy risk: Ebstein anomaly (weigh risks/benefits)

Clozapine Monitoring

Reserved for treatment-resistant schizophrenia. REMS program. Absolute neutrophil count (ANC) monitoring weekly × 6 months, every 2 weeks × 6 months, then monthly. Also screen for myocarditis (first 8 weeks), seizures (dose-related), metabolic syndrome, constipation (can be fatal — bowel obstruction).

Antidepressant Discontinuation

• SSRIs with short half-life (paroxetine, venlafaxine) — taper slowly to avoid flu-like withdrawal, "brain zaps"
• Fluoxetine has a 4-6 day half-life and active metabolite — self-tapers, minimal withdrawal
• Never stop MAOIs abruptly; 2-week washout before starting SSRI

Deep Dive: Asthma and COPD (GINA 2026 / GOLD 2026)

GINA 2026 Asthma Tracks

Track 1 (preferred for adults/adolescents): ICS-formoterol as both controller and reliever (MART/SMART strategy).

Track 2 (SABA reliever): lower priority; recognized as inferior but used when Track 1 not feasible.

Key shift in recent years: short-acting beta-agonist (SABA) monotherapy is no longer recommended. All asthma patients need some ICS exposure.

GOLD 2026 COPD Groups

ABE classification replaces the older ABCD (2023+). Assess by exacerbation history:

• Group A (few symptoms, low exacerbation risk): bronchodilator (SABA or LAMA or LABA)
• Group B (more symptoms, low exacerbation risk): LABA + LAMA
• Group E (exacerbations ≥2/year or ≥1 hospitalization): LABA + LAMA; add ICS if eosinophils ≥300

Key COPD meds: tiotropium (Spiriva), olodaterol, umeclidinium/vilanterol, tiotropium/olodaterol, fluticasone/umeclidinium/vilanterol (Trelegy triple). ICS monotherapy is NOT appropriate for COPD.

Deep Dive: Pain Management and Opioid Stewardship

Opioid Equianalgesic Conversions (Approximate Oral)

Rotation rule: when switching opioids due to tolerance or side effects, reduce the calculated equianalgesic dose by 25-50% due to incomplete cross-tolerance. Methadone requires ECG (QTc) and specialist guidance.

Naloxone Co-Prescribing

CDC recommends naloxone co-prescribing for patients on ≥50 MME/day, concurrent benzodiazepine, history of overdose, or respiratory disease. Available as intranasal spray (4 mg, 8 mg) or IM auto-injector.

NSAID Risk Stratification

Renal risk: all NSAIDs reduce prostaglandin-mediated afferent arteriole dilation. High-risk combo: NSAID + ACEI/ARB + diuretic ("triple whammy") — major AKI risk.

GI risk: add PPI if ≥2 risk factors (age ≥65, high-dose NSAID, corticosteroid, anticoagulant, prior GI bleed). Celecoxib has lower GI risk but similar cardiovascular risk.

Best NAPLEX Study Resources for 2026

No single resource is magic. A strong 2026 prep stack typically combines one primary review course with targeted supplements.

Tier 1 (pick one as your core)

• UWorld RxPrep NAPLEX Course Book (2026 edition) — the most-used core review book; pairs with UWorld RxPrep QBank for integrated practice
• UWorld RxPrep QBank — large clinical question bank with detailed rationales and analytics
• APhA Complete Review for Pharmacy, 13e — disease-state summaries + 900+ practice questions

Tier 2 (supplements)

• Comprehensive Pharmacy Review for NAPLEX (Shargel) — deeper science/PK reinforcement
• ProntoPass — highly regarded for pharmaceutical calculations drills and flashcards
• Pre-NAPLEX Official Practice Exam ($75) — the only NABP-written practice exam; take it 1-2 weeks before your test

Tier 3 (free)

• Your NAPLEX question bank on OpenExamPrep
• NABP Content Outline PDF (read it twice)
• Medscape, UpToDate (clinical verification during error review)

---

Begin Your FREE NAPLEX Prep Now

Begin FREE NAPLEX Study NowPractice questions with detailed explanations

Join thousands of PharmD candidates using our 100% FREE NAPLEX question bank, calculation drills, and AI-powered disease-state explanations.

---

Test-Day Tips: The 6-Hour Marathon

1. Pace to ~1.6 minutes per question. 225 questions over 6 hours is about 1 minute 35 seconds each. Stay on pace.
2. Use both 10-minute breaks. Do not skip them. Hydrate and eat a small carb + protein snack. Decision fatigue is real at item 150.
3. You cannot go back. Commit to each answer. If truly unsure, use elimination and move on — dwelling costs you later items.
4. Constructed response questions (fill-in-the-blank calculations) require the correct unit and rounding. Always include units in your scratch work.
5. Ordered response items require all steps correct — practice these in your final 10 days.
6. Arrive 30 minutes early. Bring two forms of ID. Store everything else in the locker — no phones, watches, or food at the testing station.

Common Pitfalls That Cause Failure

MPJE: The Other Exam You Need (Separate from NAPLEX)

The Multistate Pharmacy Jurisprudence Examination (MPJE) is the state pharmacy law exam. It is separate from NAPLEX and required for licensure in most states.

You must pass the MPJE for each state you want to be licensed in (California uses a separate CPJE). Pass rates are notably lower than NAPLEX and state law memorization is the deciding factor. Most candidates use state-specific MPJE review books (e.g., "MPJE California Pharmacy Law Study Guide").

Pharmacist Career & Salary Outlook for 2026

Once you pass the NAPLEX and MPJE and receive your pharmacist license, here is what the 2026 market looks like.

Where Pharmacists Work

• Retail/community (largest share): CVS, Walgreens, Kroger, independents — front-line dispensing, immunizations, counseling
• Hospital (~25%): inpatient order verification, IV compounding, clinical rounding
• Ambulatory care / clinical (growing): MTM, anticoagulation clinics, transitions of care, disease management
• Industry: pharma medical affairs, drug safety, regulatory, medical science liaison
• Managed care / PBM: formulary, prior auth, utilization management
• Long-term care, specialty, nuclear, informatics, academia, government (VA, IHS, military)

License Renewal

License renewal is state-specific. Most states require 15 hours of continuing pharmacy education (CPE) per year (30 hours per 2-year cycle), with specific hour requirements for live credit, patient safety, opioid/controlled substance topics, and immunization recertification (for immunizing pharmacists). Always check your state board of pharmacy for exact CE requirements.

After NAPLEX: BPS Specialty Board Certifications

After you have been licensed and practicing (most BPS certifications require 3-4 years of post-licensure experience, OR a PGY1 residency plus 1-2 years, OR passing the specialty exam), you can pursue Board of Pharmacy Specialties (BPS) certifications. These drive salary leverage, especially in clinical and ambulatory roles.

Recertification is required every 7 years through either the BPS recertification exam or an approved professional development program.

Official Sources Used

• NABP NAPLEX page (nabp.pharmacy/programs/examinations/naplex/)
• NABP NAPLEX Content Outline (effective May 1, 2025, governing 2026 exam)
• NABP Ten-Year NAPLEX and MPJE Pass Rates report (prepared February 2026)
• NABP 2026 NAPLEX/MPJE Application Bulletin
• Pearson VUE NABP testing information
• BPS (Board of Pharmacy Specialties) specialty certification eligibility pages
• U.S. Bureau of Labor Statistics — Pharmacist occupation data (2024 release)

---

Start Your FREE NAPLEX Prep Today

Start FREE NAPLEX Practice QuestionsPractice questions with detailed explanations

Every NABP domain, every calculation category, every high-yield disease state — with AI-powered rationales and a full-length 225-question mock. 100% FREE.